Analysis of clinical effect of azacitidine combined with CAG regimen on treatment of relapsed/refractory acute myeloid leukemia
10.3760/cma.j.cn115356-20191211-00246
- VernacularTitle:阿扎胞苷联合CAG方案治疗复发难治急性髓系白血病临床效果分析
- Author:
Gongai WANG
1
;
Kewei XUE
;
Shumei LI
;
Yunliang HAO
;
Shasha DONG
Author Information
1. 山东省济宁市第一人民医院血液内科 272100
- From:
Journal of Leukemia & Lymphoma
2020;29(3):157-159
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical effect of azacitidine combined with CAG regimen on the treatment of relapsed/refractory acute myeloid leukemia (AML).Methods:The data of 50 patients with relapsed/refractory AML (non-acute promyelocytic leukemia) in Jining No. 1 People's Hospital from September 2018 to September 2019 was retrospectively analyzed, and the patients were divided into the control group and the test group according to the different treatment drugs. The control group (28 cases) was treated with CAG regimen alone, and the test group (22 cases) was treated with azacitidine combined with CAG regimen. The total effective rate and adverse reactions of the two groups were observed after 1 course of treatment.Results:After one course of treatment, the total clinical effective rate in the test group was 86% (19/22), and the rate in the control group was 71% (20/28), there was a statistically significant difference between the two groups (χ 2 = 5.273, P < 0.05). There were no significant differences in the incidence of adverse reactions such as fever, pulmonary infection, vomiting, and thrombocytopenia between the two groups (all P > 0.05). Conclusion:Azacitidine combined with CAG regimen in the treatment of relapsed/refractory AML can improve the clinical efficacy without increasing the adverse reactions.
